23ME-00610 an investigational antibody drug
What is an Antibody Treatment?
23ME-00610 is an first-in-class, investigational antibody drug developed by 23andMe Therapeutics scientists. It tightly binds the immune checkpoint CD200R1 produced on the surface of immune cells.
Antibodies are natural proteins your body makes as part of the immune response. They help you fight off threats by binding to proteins from viruses and bacteria.
23andMe Therapeutics has adapted the way antibodies work to target the proteins used by cancer cells.
Certain cancers make proteins that bind to immune cells, stopping your body from recognizing the cancer. This lets them hide from your immune system.
Antibody treatments can bind to tumor-cell proteins, or to immune cells that interact with cancer cells. Once the treatment blocks the tumor cell protein from interacting with immune cells, it can help
- Prevent the cancer from hiding from your immune system
- Kill the cancer directly
How does 23ME-00610 work?
23ME-00610 was shown to activate immune cells from patient samples. It was also shown to restore the ability of T cells to kill cancer cells in a lab model of a human tumor.
A Phase 1/2a Clinical Trial
The first-in-class drug 23ME-00610 is currently being studied in a Phase 1/2a clinical trial in patients with advanced solid malignancies.
Read more about 23andMe's immuno-oncology target identification technique and the development of 23ME-00610.
- AACR 2023 Genetics Poster
First-in-class Anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies: Phase 1 PosterDownload
- AACR 2023 Abstract
First-in-class Anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies: Phase 1 AbstractDownload
- SITC 2022 Trials in Progress poster
A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid MalignanciesDownload
- AACR 2022
23ME-00610 Is a First-in-Class Monoclonal Antibody That Targets the CD200R1 Immune Checkpoint to Enhance T-Cell–Mediated Antitumor ActivityDownload
- AACR 2022
Discovery of CD200R1 as a Novel Immuno-oncology Target Using Pleiotropic Signals From 23andMe’s Genetic and Health Survey DatabaseDownload
Read more about the development of 23ME-00610 in the following press releases.
- 23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented.View Press Release at 23andMe
- 23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies.
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610.View Press Release at 23andMe
- 23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting.
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity.View Press Release at 23andMe
- 23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting.
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies.View Press Release at 23andMe
Be one of the first to get updates
Connect with us to receive information about the 23ME-00610 clinical trial and more.